{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:10Z","timestamp":1793295850440,"version":"4.5.0"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis, with an estimated incidence of at least 2.5 per 10 000 adults per year. The long-term outcomes remain poor, particularly for patients with proteinuria greater than 0.44\u2005g\/g (approximately 500\u2005mg\/day) and an estimated glomerular filtration rate (eGFR) decline of more than 1\u2005mL\/min\/1.73\u2005m2. The recently revised KDIGO guidelines acknowledged the new cutoffs for high-risk patients and proposed lower proteinuria and eGFR-loss goals. New insights into pathophysiology and approval of proteinuria as a surrogate parameter led to a surge in IgAN treatment research. Supportive chronic kidney disease (CKD) care is still considered the basis for every IgAN, and therapies like renin-angiotensinsystem inhibitors (RASi) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) should be established for every patient. Systemic glucocorticoids are still considered first-line treatment for high-risk IgAN and are recommended in current guidelines. However, the prospective data in the TESTING and STOP-IgAN trials are conflicting and more recent retrospective data suggest poor efficacy of glucocorticoids in Caucasian patients. Other immunosuppressive therapies, like Mycophenolate Mofetil (MMF), do seem to lead to better outcomes in Chinese subjects, however, the current data do not support their use in other ethnicities. In conclusion, following the most recent pathophysiology insights, new emerging therapies like TRF-budesonide, ETA-receptor antagonists, B-cell modulation and depletion therapies, and complement inhibitors seem to be quickly replacing current treatment standards. One of the big challenges in the next years will be how to implement new emerging treatments, establishing induction and maintenance protocols, and developing new biomarkers and biopsy criteria to guide the use of novel medications.<\/jats:p>","DOI":"10.1093\/joneph\/aajaf056","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:24:30Z","timestamp":1767702270000},"page":"37-49","source":"Crossref","is-referenced-by-count":1,"title":["Immunoglobulin A nephropathy\u2014novel insights in long-term outcomes and pathophysiology leading to international guideline modification and new emerging therapies"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7755-0735","authenticated-orcid":false,"given":"Martin","family":"Klein","sequence":"first","affiliation":[{"name":"South West Healthcare, Warrnambool Base Hospital , Department of General Medicine, 25 Ryot St, Warrnambool, VIC 3280 ,","place":["Australia"]},{"name":"St. Vincent's Hospital Melbourne , Department of Nephrology, 41 Victoria Parade, Fitzroy, VIC 3065 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Roberts","sequence":"additional","affiliation":[{"name":"St. Vincent's Hospital Melbourne , Department of Nephrology, 41 Victoria Parade, Fitzroy, VIC 3065 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad M","family":"Javaid","sequence":"additional","affiliation":[{"name":"South West Healthcare, Warrnambool Base Hospital , Department of General Medicine, 25 Ryot St, Warrnambool, VIC 3280 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026060416371927800_aajaf056-B1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416371927800_aajaf056-B2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060416371927800_aajaf056-B3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: a call for a new paradigm","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"2026060416371927800_aajaf056-B4","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"2026060416371927800_aajaf056-B5","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2026060416371927800_aajaf056-B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"2026060416371927800_aajaf056-B7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/jcm13040947","article-title":"An update on current therapeutic options in IgA nephropathy","volume":"13","author":"Lim","year":"2024","journal-title":"J Clin Med"},{"key":"2026060416371927800_aajaf056-B8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060416371927800_aajaf056-B9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"2026060416371927800_aajaf056-B10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int"},{"key":"2026060416371927800_aajaf056-B11","author":"Floege"},{"key":"2026060416371927800_aajaf056-B12","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why target the gut to treat IgA nephropathy?","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026060416371927800_aajaf056-B13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/bj2710285","article-title":"The structure and function of human IgA","volume":"271","author":"Kerr","year":"1990","journal-title":"Biochem J"},{"key":"2026060416371927800_aajaf056-B14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1681\/ASN.2007091052","article-title":"Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy","volume":"19","author":"Gharavi","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2026060416371927800_aajaf056-B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1172\/JCI5535","article-title":"Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies","volume":"104","author":"Tomana","year":"1999","journal-title":"J Clin Invest"},{"key":"2026060416371927800_aajaf056-B16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fimmu.2016.00117","article-title":"The origin and activities of IgA1-containing immune complexes in IgA nephropathy","volume":"7","author":"Knoppova","year":"2016","journal-title":"Front Immunol"},{"key":"2026060416371927800_aajaf056-B17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.kint.2024.07.033","article-title":"The mucosal microbiome and IgA nephropathy: a new target for treatment?","volume":"106","author":"Selvaskandan","year":"2024","journal-title":"Kidney Int"},{"key":"2026060416371927800_aajaf056-B18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2026060416371927800_aajaf056-B19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000519973","article-title":"New insights into the pathogenesis and treatment strategies in IgA nephropathy","volume":"2","author":"Scionti","year":"2022","journal-title":"Glomerular Dis"},{"key":"2026060416371927800_aajaf056-B20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ekir.2021.02.018","article-title":"Supportive management of IgA nephropathy with renin-angiotensin blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) study","volume":"6","author":"Bagchi","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026060416371927800_aajaf056-B21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.amjmed.2012.06.028","article-title":"Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor","volume":"126","author":"Li","year":"2013","journal-title":"Am J Med"},{"key":"2026060416371927800_aajaf056-B22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2026060416371927800_aajaf056-B23","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2026060416371927800_aajaf056-B24","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies G","year":"2022","journal-title":"Lancet"},{"key":"2026060416371927800_aajaf056-B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026060416371927800_aajaf056-B26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2026060416371927800_aajaf056-B27","doi-asserted-by":"publisher","first-page":"bqac150","DOI":"10.1210\/endocr\/bqac150","article-title":"The human glucocorticoid receptor beta: from molecular mechanisms to clinical implications","volume":"163","author":"Nicolaides","year":"2022","journal-title":"Endocrinology"},{"key":"2026060416371927800_aajaf056-B28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"2026060416371927800_aajaf056-B29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2026060416371927800_aajaf056-B30","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"2026060416371927800_aajaf056-B31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12882-024-03481-6","article-title":"Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study","volume":"25","author":"Rivedal","year":"2024","journal-title":"BMC Nephrol"},{"key":"2026060416371927800_aajaf056-B32","doi-asserted-by":"publisher","first-page":"e30422","DOI":"10.1097\/MD.0000000000030422","article-title":"Immunosuppressive therapy versus supportive care in IgA nephropathy patients with stage 3 and 4 chronic kidney disease","volume":"101","author":"Stefan","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2026060416371927800_aajaf056-B33","doi-asserted-by":"publisher","first-page":"e0268421","DOI":"10.1371\/journal.pone.0268421","article-title":"The epidemiology and evolution of IgA nephropathy over two decades: a single centre experience","volume":"17","author":"Storrar","year":"2022","journal-title":"PLoS One"},{"key":"2026060416371927800_aajaf056-B34","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/ndt\/gfac221","article-title":"TESTING the effects of corticosteroids in patients with IgA nephropathy","volume":"37","author":"Seikrit","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416371927800_aajaf056-B35","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416371927800_aajaf056-B36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026060416371927800_aajaf056-B37","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"2026060416371927800_aajaf056-B38","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"2026060416371927800_aajaf056-B39","doi-asserted-by":"publisher","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026060416371927800_aajaf056-B40","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/ndt\/gfae214","article-title":"Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application","volume":"40","author":"Moedt","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416371927800_aajaf056-B41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","article-title":"Endothelin receptor antagonists in chronic kidney disease","volume":"21","author":"Smeijer","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"2026060416371927800_aajaf056-B42"},{"key":"2026060416371927800_aajaf056-B43"},{"key":"2026060416371927800_aajaf056-B44","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"2026060416371927800_aajaf056-B45","author":"Cheung"},{"key":"2026060416371927800_aajaf056-B46","author":"Cheung"},{"key":"2026060416371927800_aajaf056-B47","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"2026060416371927800_aajaf056-B48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ekir.2024.10.004","article-title":"Study design and baseline characteristics of ALIGN, a randomized controlled study of atrasentan in patients with IgA nephropathy","volume":"10","author":"Heerspink","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026060416371927800_aajaf056-B49","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416371927800_aajaf056-B50","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/MOG.0000000000000789","article-title":"Role of gut-kidney axis in renal diseases and IgA nephropathy","volume":"37","author":"Monteiro","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"2026060416371927800_aajaf056-B51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5339\/qmj.2024.22","article-title":"Evolving therapeutic strategies in IgA nephropathy: from conservative management to targeted interventions","volume":"2024","author":"Abuhelaiqa","year":"2024","journal-title":"Qatar Med J"},{"key":"2026060416371927800_aajaf056-B52","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"2026060416371927800_aajaf056-B53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"2026060416371927800_aajaf056-B54","doi-asserted-by":"publisher","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026060416371927800_aajaf056-B55","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","article-title":"The role of APRIL and BAFF in lymphocyte activation","volume":"17","author":"Schneider","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"2026060416371927800_aajaf056-B56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"2026060416371927800_aajaf056-B57"},{"key":"2026060416371927800_aajaf056-B58","author":"Murphy"},{"key":"2026060416371927800_aajaf056-B59","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026060416371927800_aajaf056-B60","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/ckj\/sfad041","article-title":"Future landscape for the management of membranous nephropathy","volume":"16","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026060416371927800_aajaf056-B61","doi-asserted-by":"publisher","first-page":"gfae069-0139-425","DOI":"10.1093\/ndt\/gfae069.139","article-title":"Felzartamab (anti-CD38) in patients with IgA nephropathy\u2014interim results from the IGNAZ study (abstract)","volume":"39","author":"Floege","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416371927800_aajaf056-B62","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","article-title":"Iga nephropathy: the lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"2026060416371927800_aajaf056-B63","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1093\/ndt\/gfad140","article-title":"The complement system in IgAN: mechanistic context for therapeutic opportunities","volume":"38","author":"Duval","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416371927800_aajaf056-B64","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/nep.14347","article-title":"Utilizing complement inhibition in IgA nephropathy","volume":"29","author":"Lafayette","year":"2024","journal-title":"Nephrology (Carlton)"},{"key":"2026060416371927800_aajaf056-B65","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2026060416371927800_aajaf056-B66","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial","volume":"36","author":"Lafayette","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026060416371927800_aajaf056-B67","doi-asserted-by":"publisher","first-page":"1461879","DOI":"10.3389\/fmed.2024.1461879","article-title":"Therapy of IgA nephropathy: time for a paradigm change","volume":"11","author":"Barratt","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026060416371927800_aajaf056-B68","author":"The World Health Organization"},{"key":"2026060416371927800_aajaf056-B69","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/ndt\/gfae085","article-title":"Albuminuria predicts kidney events in IgA nephropathy","volume":"40","author":"Faucon","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026060416371927800_aajaf056-B70","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026060416371927800_aajaf056-B71"},{"key":"2026060416371927800_aajaf056-B72","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.1016\/j.ekir.2024.02.362","article-title":"WCN24-1837 beyond: a phase 3, randomized, double-blind, placebocontrolled trial of zigakibart in adults with IGA nephropathy","volume":"9","author":"Trimarchi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026060416371927800_aajaf056-B73","doi-asserted-by":"publisher","first-page":"S505","DOI":"10.1016\/j.ekir.2024.02.1411","article-title":"WCN24-762 updated results from the RUBY-3 study of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in autoantibody-associated glomerulonephritis","volume":"9","author":"Tumlin","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026060416371927800_aajaf056-B74"},{"key":"2026060416371927800_aajaf056-B75"},{"key":"2026060416371927800_aajaf056-B76","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060416371927800_aajaf056-B77"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/1\/37\/68090290\/aajaf056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/1\/37\/68090290\/aajaf056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:37:25Z","timestamp":1780605445000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/1\/37\/8655068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,16]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajaf056","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]}}}